1

Our Vision
“To be recognised as a trusted
and respected leader in our
chosen healthcare segments in
Asia Pacific and Africa”

2
Contents Introducing iNova Pharmaceuticals 7

Our Mission, Vision & Values 8

Sales, Marketing & Our Therapy Areas 10

New Product Development 11

Manufacturing, Quality & Supply Chain 12

Regulatory Affairs 13

Our Place in the Region 14

How to Contact Us 15

3
Andrew Howden
Chief Executive Officer
iNova Pharmaceuticals

As the global pharmaceutical industry faces increasing challenges, iNova Pharmaceuticals is uniquely
poised to strengthen its position in a highly competitive environment.
We have an established portfolio of consumer healthcare and prescription brands across the fastest
growing region in the world. We also have appropriate and flexible infrastructure to manage and
grow our business, which enables rapid responses to changing customer needs.
Combined with the strong support of our Board and Management, iNova is building an organisation
with the strategic and operational excellence to rapidly take advantage of opportunities that will
benefit patients, our customers and future business. Above all, we have enthusiastic dedicated teams
across many countries and sales and marketing partners who are passionate about iNova and the
customers to whom we are accountable.
Our key focus is to create value for patients and consumers. That is, the value of clinically proven
medicines, value for money to end users, and value in improving their quality of life. In turn, we
believe our focus on patient and consumer value will return as shareholder value.
Patients and Consumers already experience value from iNova products in a number of therapy areas
including pain management, allergy, dermatology, cardiology, respiratory, sexual health and weight
management. We aim to continue strengthening our portfolio with new opportunities that will add
patient value in new therapy areas.
iNova products are providing value for patients and consumers in over 15 countries across the Asia-
Pacific and in Africa. We will continue to build our business and reputation in this region with leading
brands in several therapy areas.
As in all successful organisations, iNova’s priority is its people. We will ensure we have a reputation
as a clear market leader in our industry, which can only be achieved with market leading people who
have the highest ethical and professional standards.
So with this in mind, our corporate brochure outlines who we are, our values, people, capabilities
and therapy areas, as well as future directions for growing our business.
Indeed, as our industry undergoes various changes in the future, we believe iNova will be at the
forefront in leading positive change for better outcomes, for all parties.

Andrew Howden
Chief Executive Officer

4
Our Mission
“To improve human health
and well being by providing
valued pharmaceutical
products and services”

5
 Our Values
“At iNova we add value through;
Our people, our products
our integrity and our customers”

6
Introducing iNova Pharmaceuticals
Overview

iNova Pharmaceuticals (Australia) Pty Limited is an Australian owned and operated pharmaceutical company that is the
corporate headquarters for iNova Pharmaceuticals (“iNova”) operations. iNova has leading consumer healthcare and
specialty prescription brands in over 15 countries, including Australia, New Zealand, Asia Pacific and Africa regions.

Borne out of more than 50 years heritage from Riker Laboratories and 3M Pharmaceuticals following the November
2006 purchase of 3M’s Asia-Pacific pharmaceutical business by Australian private equity firms Archer Capital and
Ironbridge Capital. iNova is committed to meeting patient and consumer needs in providing value adding healthcare
solutions that improve people’s health and well being.

iNova has a broad spectrum of capabilities involving the company’s dedicated business units and business partners to
extend product brands into new and existing markets. Our focus is on delivering high quality sales and marketing for the
important brands we support. We have further key capabilities which include in-licensing, developing and acquiring products,
alongside manufacturing, quality and regulatory processes, which are overseen from iNova’s corporate headquarters
at Thornleigh in Sydney. Our manufacturing site in Sydney is GMP certified and provides products in tablet, capsule,
lozenge, liquid, cream and gel formulations for Australia and export markets in Asia, Africa, Europe and the Americas.

iNova’s flexible business model also allows the company to enter various partnerships and successfully export to countries
such as Japan, Korea and China. We therefore work with sales and marketing business partners and pharmaceutical
companies in other countries to make our products available to the broader global community. iNova is able to successfully
launch products (licensed-in or developed in-house) throughout Asia, South Africa, Australia and New Zealand.

Fundamental to strengthening iNova’s future product pipeline will be new opportunities bringing patient and consumer
value in selected therapy areas. With its flexibility, established infrastructure and proven track record, iNova is an
attractive licensing partner for companies planning to enter the Asia-Pacific and Africa regions.

7
Our Mission
To improve human health and well being by providing valued pharmaceutical products and services.

Our Vision
To be recognised as a trusted and respected leader in our chosen healthcare segments in Asia-Pacific
and Africa:

• consistently delivering value to patients, customers, employees and shareholders;

• where people value speed, simplicity and efficient delivery on our promises;
• accountable for the environmental, social and economic impact of our actions;
• with a Top 3 selling product in key therapy areas where we compete;
• with sustainable growth that doubles our business every five years.

8
Our Values
At iNova we add value through:

Our People - We are passionate about nurturing people on a professional and personal level
Our Products - We take pride in and are committed to excellence at every stage of the product cycle
Our Integrity - We are ethical in all that we do and say
Our Customers - We listen to customers, understand their needs and aim to consistently meet their expectations

Strategic Focus
Our key strategic focus is to create value by:

• Building pipeline via focused investment in Business Development (acquisitions and in-licensing) in
consumer healthcare and prescription brands for Australasia, Asia-Pacific and Africa regions.
• Sharpening sales and marketing execution capabilities to achieve our growth objectives.
• Expand geographical reach and create value in key markets including Australia, China, Southeast Asia,
South Africa, Korea and Japan to become partner of choice for companies wishing to launch and market
their product in these regions.
• Generate tangible return on capital and investment, managing costs and capital for operating profit (EBITDA)
growth.

9
 Sales and Marketing
iNova is a specialty healthcare organisation with over 100
in-house sales and marketing personal operating across the
region, supplemented by contract sales teams within Asia.
A key element of our success is the relentless pursuit of
high quality sales and marketing execution in every market.

We aim to be recognised as an industry leader in sales

and marketing productivity with high levels of disease state
and product knowledge. Supporting these goals is our
commitment to ensuring a core competency in effective
sales and marketing execution that drives iNova business
strategy in creating value for patients and consumers.

High quality interactions with healthcare professionals are

pivotal to creating patient and consumer value. Our key
customers include primary care physicians, dermatologists,
pain specialists, weight management specialists, sexual
health physicians, surgeons, and pharmacists, as well as
key accounts within the healthcare profession.

In particular, we are committed to providing service, support and educational materials that enable health care
professionals to optimise health outcomes for their patients. The driving force behind effective sales and marketing
implementation are iNova’s people, marketing strategies, innovative customer training programs, sales tactics and a
genuine commitment to delivering excellence in all that we do in consistently meeting our customers’ needs.

Our Therapy Areas

iNova has major market leading products in prescription pharmaceuticals and consumer healthcare. Our current
prescription medicines portfolio mainly includes therapies in analgesia, dermatology, cardiology, respiratory, sexual
health and weight management.

We also have a diverse range of consumer healthcare products as effective treatment options for several conditions.
These brands are available in pharmacy and include our recently introduced “A to Zep” in-licensed range of allergy
products for hayfever, urticaria and allergic conjunctivitis. The range includes Azep®, Eyezep®, ZepAllergy® and
ZepClear® brands (Eyezep® and Azep® are registered trademarks of MEDA Pharma GmbH & Co. KG).

10
Other iNova brands are developed and manufactured
in Australia, and distributed in Australia, Sub-Saharan
Africa and many Asian markets. Our Duro-Tuss®
and Difflam® brands hold strong market positions
across our key categories of cough and sore throat,
respectively, and are among the top two selling brands
in several countries. Duro-Tuss (Pholtex® in South
Africa) has a 30 year plus heritage, representing today
an extensive range of dry and chesty cough products
in both liquid and lozenge formats. Difflam (Andolex®
in South Africa) has a strong medicinal heritage with
an effective anti-inflammatory active, benzydamine
hydrochloride, contained in single and combination
formulations to meet differing health needs. Suitable
for sore throats and painful mouth conditions, Difflam
is available in a wide variety of flavours and formats,
lozenges, sprays, solutions, gels and gargles that
caters for choice. Other brands iNova manufactures and
markets include Metsal®, Cal-Sup® and Hiprex®.
Our products are prescribed by specialist health care
providers and general practitioners across the Region
and supported by pharmacy recommendation.
The origins of our diverse medicines portfolio come
from a heritage of many years of innovation and, more
recently, in-licensed products. In the development and
manufacturing of our products, quality assurance and
control, operational excellence, integrity and innovation
help to ensure iNova produces and markets brands
that meet the most rigorous quality standards.
Looking ahead, there is a strong research driven
pipeline of product innovation that will be used to build
brands in their existing markets, as well as broaden
distribution throughout the Asia-Pacific region.

New Product Development

Our New Product Development team is constantly searching for innovative new prescription and consumer healthcare
medicines in transforming potential opportunities into real healthcare solutions. To enable this, iNova’s expertise and
dedicated marketing resources in Australia, Asia and South Africa are crucial for the successful introduction of products
into new markets.

With established therapy franchises in analgesia, allergy, dermatology, weight management, sexual health, respiratory,
and cardiology, as well as a growing and diverse in-licensed pipeline, we aim to bring valued medicines to many
markets, maximising awareness and utilisation of these products.

An integral part of our business strategy is partnerships, and we invite licensing and co-marketing proposals from
pharmaceutical companies seeking growth opportunities in the Asia-Pacific and Southern African regions.

Complementing our in-house licensing expertise is a dedicated team of highly skilled chemists focused on expanding
iNova’s healthcare consumer portfolio with novel formulations and dose forms that optimise drug delivery and product
quality. Among other initiatives, our in-house skills in consumer healthcare product development have resulted in
the successful introduction of many line extensions for Duro-Tuss® and Difflam® brands, and more innovative new
products are planned for the future.

11
Manufacturing and Quality
iNova manufactures pharmaceuticals in liquid and solid dosage forms into a variety of finished product presentations
at the iNova Technology Centre in Sydney. This is a certified Therapeutic Goods Administration (TGA) licensed GMP
Pharmaceutical Manufacturing Facility with ISO 14001 Environmental Management System Certification.

The iNova Technology Centre represents a major investment in 21st Century energy efficient and environmentally
friendly technologies and processes. The Centre houses state of the art features such as:

• Research and development pilot plant and laboratories;

• Fully equipped analytical chemistry and microbiology quality control and laboratories;
• Manufacturing facilities for solids, liquids, cream products, bottles and blister packaging.

With over 170 employees at the Centre including manufacturing staff; mechanical, process and validation engineers,
research and product development chemists, analytical chemists and microbiologists, our current production capacity
annually includes 570 million tablets; 2.5 million litres of liquid products; 15.6 million blister packing platforms
and 6.75 million tubes for topical preparations. iNova employs a full SAP Enterprise Resource Planning system
to ensure efficiencies and effectiveness in delivering the highest level of customer service. This system integrates
our manufacturing processes, resource and operations planning, inventory, warehousing and distribution, financial
management, purchasing and customer service functions.

Supply Chain
iNova supply chain management and logistics include the sales and operations planning process, customer relationship
and warehouse and distribution The synergies of these operations represent a world class supply chain for the “on
time and in full” supply of products to our markets so that when customers want a product they get it. Our focus is to
provide efficient customer service with minimal lead times in delivering products so customers receive the real value
of our products.

Particular strengths of our supply chain include:

• Simplified customer service processes that make it easy to do business with iNova;
• Continuous improvement in sales and operations planning to enable ongoing forecast accuracy and optimal
product cost and delivery from all supply sources;
• Centralised warehousing operations that ship iNova products to wholesalers and third party distributors
throughout Australia, New Zealand, Asia-Pacific and Sub-Saharan Africa, as well as other international
markets.

12
Regulatory and Medical Affairs
iNova recognises competitive advantage by being Our activities support the appropriate prescribing
proactive with compliance, product development and and use of approved products and responsible
marketing authorisation requirements. Our in-house marketing promotion via a comprehensive medical
Regulatory and Medical Affairs capability is broad communications service for external and internal
ranging, diverse and commercially aware with a team customers. We have high competencies in risk
experienced in new product applications, medical management processes such as promotional
communications and reimbursement processes. materials review and pharmacovigilance, as well as
reimbursement submissions to maximise market
This capability enables iNova to recognise opportunity, access to our brands.
competitive advantage and create value by initiating
activities to ensure timely product approvals in a
highly regulated and regionally diverse industry
environment. In particular, we have successfully
completed drug and medical device submissions
and gained approvals across a wide range of therapy
areas. These include a first-in-class immune response
modifier with two different approved dermatology
indications and an indication in sexual health, as
well as fast tracked submissions for numerous
consumer healthcare products in cough and sore
throat categories, novel drugs and medical devices.

Environmental Health
and Safety
Environment
iNova is committed to operating an environmentally sustainable business and has a longstanding reputation in
the local and international community for environmental leadership. This is managed through an Environmental
Management System accredited to ISO14001:2004. Resource utilisation is a major focus for our operations group
with programs in place to reduce energy and water usage. iNova has an ongoing commitment to reducing the
amount of waste generated by our operations and supply chain.

Our environmental programs include:

• Rollout of a recycling initiative to reduce waste generated on site that ends up in landfill;
• Upgrade of a waste water treatment plant;
• Installation of new air compressors to deliver significant savings in electricity usage;
• Utilisation of new recycling technology to dispose of waste previously considered non-recyclable.

Occupational Health & Safety

Historically, iNova and its predecessor, 3M Company, have had an ongoing focus to provide a safe and healthy work
environment for all employees, contractors, visitors and the general public. Specifically, we strive to have a workplace
free of incidents and injury by identifying hazards and reducing risks. We pursue this by continuously improving our
health and safety programs and having a collective responsibility for safe work practices driven by all managers,
supervisors and staff.

13
Our Place in the Region

Korea
Japan
China
Taiwan
Thailand
Malaysia Philippines
Singapore

AUSTRALIA
South Africa

iNova Offices New Zealand

Country Business Partners
Australia Philippines
iNova Pharmaceuticals (Australia) Pty Limited iNova Pharmaceuticals (Philippines).Inc
9-15 Chilvers Road Unit 28-B Ayala Life-FGU Center
Thornleigh NSW 2120 6811 Ayala Avenue, Makati City
Australia Philippines
Tel: +61 2 9875 6333 Tel: +632 840 4741
South Africa Singapore
iNova Pharmaceuticals (Pty) Limited iNova Pharmaceuticals (Singapore) Pte Limited
15e Riley Road 10 Ubi Crescent
Bedfordview 02-51 Ubi Techpark, Singapore 408564
Private Bag 3115 Tel: +65 6742 3116
Bedfordview 2008
Republic of South Africa
Thailand
Tel:+27 11 021 4155 iNova Pharmaceuticals (Thailand) Limited
50 GMM Grammy Place Building 12th Floor,
Hong Kong Unit B5, Sukhumvit 21 Road(Asoke),
iNova Pharmaceuticals (Hong Kong) Limited Klongtoeynua, Wattana, Bangkok 10110
Unit 01, 20th Floor, Millennium City 3,
370 Kwun Tong Road, Kwun Tong, Kowloon Thailand
Hong Kong Tel: +66 2 665 9055
Tel: +852 2117 9228
DKSH Taiwan Ltd
Malaysia 10F, No 22, Lane 407, Ti-Ding Blvd,
iNova Pharmaceuticals (Singapore) Pte Ltd Section 2
(Malaysia Branch) (995059W) Neihu Technology Park
Level 5, Wisma Samudra Taipei 114, Taiwan, R.O.C.
No. 1, Jalan Kontraktor U1/14
Hicom-Glenmarie Ind. Park Distributor/Partner Arrangements with iNova
40150 Shah Alam, Malaysia Pharmaceuticals
Tel: +603 5569 1278 China
Japan
Korea
New Zealand

14
How to Contact Us Corporate Headquarters
iNova Pharmaceuticals
(Australia) Pty Limited

9-15 Chilvers Road

Thornleigh NSW 2120
Australia

PO Box 101
Pennant Hills NSW 2120
Australia
Tel: +61 2 9875 6333
Fax: +61 2 9875 6416

www.inovapharma.com

ABN 88 000 222 408

15